menu
    • menu
    [{"orgOrder":0,"company":"Papillon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"PPL-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Papillon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Papillon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Papillon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Papillon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"PPL-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Papillon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Papillon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Papillon Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Papillon Therapeutics

    Menu

    Papillon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Papillon Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Papillon Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PPL-002

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Papillon Therapeutics Receives Orphan Drug Designation For PPL-002 in Danon Disease

                            Details : PPL-002 is an experimental gene-modified CD34+ hematopoietic stem and progenitor cell (HSPC) therapy, being evaluated for the treatment of Danon disease.

                            Brand Name : PPL-002

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 01, 2024

                            Lead Product(s) : PPL-002

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Papillon Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Papillon Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PPL-001

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Papillon Receives Orphan Drug Designation for PPL-001 in Friedreich's Ataxia

                            Details : PPL-001 is an experimental gene-corrected CD34+ HSPC therapy. Currently, it is being investigated for the treatment of Friedreich's ataxia.

                            Brand Name : PPL-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 17, 2024

                            Lead Product(s) : PPL-001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth